B. Metzler seel. Sohn & Co. AG Boosts Position in Boston Scientific Corporation $BSX

Key Points

• B. Metzler seel. Sohn & Co. AG increased its stake in Boston Scientific by 1.6%, owning a total of 229,394 shares, worth approximately $23.14 million.
• Several institutional investors, including Vanguard Group and Goldman Sachs, have also raised their positions in Boston Scientific, reflecting strong interest, with 89.07% of the stock owned by institutional investors.
• Boston Scientific reported a positive earnings performance, achieving $0.75 EPS which surpassed analyst expectations of $0.72, along with a revenue increase of 22.8% year-over-year for the quarter.

B. Metzler seel. Sohn & Co. AG lifted its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 1.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 229,394 shares of the medical equipment provider's stock after purchasing an additional 3,683 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Boston Scientific were worth $23,141,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after purchasing an additional 1,697,945 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of Boston Scientific by 2.5% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 22,312,967 shares of the medical equipment provider's stock valued at $1,992,994,000 after purchasing an additional 554,388 shares during the period. Invesco Ltd. lifted its stake in shares of Boston Scientific by 5.3% in the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock valued at $1,677,124,000 after purchasing an additional 834,274 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Boston Scientific by 10.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock valued at $1,426,779,000 after purchasing an additional 1,383,524 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Boston Scientific by 18.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock valued at $968,172,000 after purchasing an additional 1,709,461 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently commented on BSX. Robert W. Baird boosted their price target on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Needham & Company LLC reissued a "buy" rating and issued a $115.00 price target on shares of Boston Scientific in a report on Wednesday, May 28th. Barclays boosted their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Finally, Leerink Partners began coverage on shares of Boston Scientific in a report on Monday, June 16th. They issued an "outperform" rating and a $118.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $117.50.

Insider Activity

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the company's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $18,347,824.96. The trade was a 24.02% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 345,029 shares of company stock worth $35,976,603. Insiders own 0.50% of the company's stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $106.42 on Wednesday. Boston Scientific Corporation has a 52-week low of $79.03 and a 52-week high of $108.94. The firm has a market capitalization of $157.69 billion, a price-to-earnings ratio of 63.35, a PEG ratio of 2.53 and a beta of 0.66. The company has a fifty day simple moving average of $104.27 and a 200-day simple moving average of $102.15. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the firm earned $0.62 earnings per share. The company's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.